Skip to main content
NTRA
NASDAQ Life Sciences

Natera Is Maintained at Outperform by Baird

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
7
Price
$216.1
Mkt Cap
$29.891B
52W Low
$125.38
52W High
$256.36
Market data snapshot near publication time

summarizeSummary

Baird has maintained its 'Outperform' rating on Natera and raised its price target to $257.00 per share from $239.00. This positive analyst action follows Natera's announcement yesterday of strong Q4 and full year 2025 financial results, which likely prompted the revised valuation. The increased price target from a reputable firm reinforces a positive outlook on the company's prospects and could provide upward momentum for the stock as investors react to the analyst's updated conviction. Traders will be watching for further analyst coverage and the company's continued operational performance.

At the time of this announcement, NTRA was trading at $216.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.9B. The 52-week trading range was $125.38 to $256.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


show_chartPrice Chart

Share this article

Copied!

feed NTRA - Latest Insights

NTRA
Apr 23, 2026, 4:44 PM EDT
Filing Type: DEF 14A
Importance Score:
7
NTRA
Feb 27, 2026, 8:07 AM EST
Source: Dow Jones Newswires
Importance Score:
7
NTRA
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
NTRA
Feb 02, 2026, 4:58 PM EST
Filing Type: 144
Importance Score:
7
NTRA
Jan 12, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8